Open AccessDrug repositioning of Clopidogrel or Triamterene to inhibit influenza virus replication in vitro
Author(s) -
Nichole Orr-Burks,
Jackelyn Murray,
Kyle V. Todd,
Abhijeet Bakre,
Ralph A. Tripp
Publication year - 2021
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0259129
Subject(s) - drug repositioning , favipiravir , viral replication , drug , virus , influenza a virus , virology , medicine , triamterene , druggability , pharmacology , biology , gene , disease , covid-19 , infectious disease (medical specialty) , blood pressure , hydrochlorothiazide , biochemistry
Influenza viruses cause respiratory tract infections and substantial health concerns. Infection may result in mild to severe respiratory disease associated with morbidity and some mortality. Several anti-influenza drugs are available, but these agents target viral components and are susceptible to drug resistance. There is a need for new antiviral drug strategies that include repurposing of clinically approved drugs. Drugs that target cellular machinery necessary for influenza virus replication can provide a means for inhibiting influenza virus replication. We used RNA interference screening to identify key host cell genes required for influenza replication, and then FDA-approved drugs that could be repurposed for targeting host genes. We examined the effects of Clopidogrel and Triamterene to inhibit A/WSN/33 (EC 50 5.84 uM and 31.48 uM, respectively), A/CA/04/09 (EC 50 6.432 uM and 3.32 uM, respectively), and B/Yamagata/16/1988 (EC 50 0.28 uM and 0.11 uM, respectively) replication. Clopidogrel and Triamterene provide a druggable approach to influenza treatment across multiple strains and subtypes.